Sun Pharma Advanced Research Co

Sun Pharma Advanced Research Co Gross Margin

The Gross Margin of Sun Pharma Advanced Research Co (SPARC.NS) as of Oct 16, 2026 is 91.92 %. In the previous year, Gross Margin was 67.79 % — a change of 35.60% (higher).

Gross Margin

91.92 %

YoY

35.60%

Last updated:

Gross Margin of Sun Pharma Advanced Research Co is 2026 91.92 % . Gross Margin of Sun Pharma Advanced Research Co was 2025 67.79 % . It decreases by 35.60% higher compared to the previous year.

Sun Pharma Advanced Research Co's gross margin stands at 91.9%, up from 7.7% several years earlier.

The Sun Pharma Advanced Research Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
12.27 INR
Jan 1, 2020
-151.55 INR
Jan 1, 2021
18.40 INR
Jan 1, 2022
7.69 INR
Jan 1, 2023
34.39 INR
Jan 1, 2024
-163.91 INR
Jan 1, 2025
67.79 INR
Jan 1, 2026
91.92 INR
The Sun Pharma Advanced Research Co Gross Margin history
YEARGross MarginYoY
91.92 %+35.60%
67.79 %-141.36%
-163.91 %-576.59%
34.39 %+347.34%
7.69 %-58.23%
18.40 %-112.14%
-151.55 %-1,334.89%
12.27 %-114.57%
-84.22 %-1,626.78%
5.52 %-61.10%
14.18 %-36.96%
22.49 %-76.38%
95.21 %+10,556.76%
0.89 %+20.06%
0.74 %-14.31%
0.87 %+8.08%
0.80 %+9.59%
0.73 %-10.25%
0.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sun Pharma Advanced Research Co Stock analysis

What does Sun Pharma Advanced Research Co do? Sun Pharma Advanced Research Co Ltd, listed on the National Stock Exchange of India with ticker SPARC.NS and ISIN INE232I01014, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the healthcare sector, specifically in the pharmaceutical industry, and employs 407 full-time staff. It completed its initial public offering on July 18, 2007. Sun Pharma Advanced Research focuses on research and development of pharmaceutical products targeting unmet medical needs, particularly in the fields of oncology, neurodegeneration, and immunology. The company develops New Chemical Entities (NCEs), New Biological Entities, and reformulated products. Specific NCEs mentioned include SCC-138, SCO-088, SCO-120, and SCD-044. It also utilizes Novel Drug Delivery Systems (NDDS), such as Wrap Matrix Technology for controlled-release tablets, Lipexelle technology for ophthalmic formulations, and TearAct Technology for eye drops. Products developed using these technologies include Elepsia XR, which employs Wrap Matrix Technology, and Xelpros, a BAK-free latanoprost eye drop developed with Lipexelle technology and commercialized in the United States by a partner. Additionally, the company has created PDP-716 eye drops for glaucoma treatment using TearAct Technology. The company's website is https://www.sparc.life/. Sun Pharma Advanced Research Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sun Pharma Advanced Research Co stock

Gross Margin of Sun Pharma Advanced Research Co is 91.92 % in 2026.

Gross Margin of Sun Pharma Advanced Research Co changed from 67.79 % to 91.92 %, representing a 35.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sun Pharma Advanced Research Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sun Pharma Advanced Research Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sun Pharma Advanced Research Co

All Key Metrics — Sun Pharma Advanced Research Co